Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Association of CAG Repeats With Long-term Progression in Huntington Disease.

Langbehn DR, Stout JC, Gregory S, Mills JA, Durr A, Leavitt BR, Roos RAC, Long JD, Owen G, Johnson HJ, Borowsky B, Craufurd D, Reilmann R, Landwehrmeyer GB, Scahill RI, Tabrizi SJ; TRACK-HD and Track-On HD Groups.

JAMA Neurol. 2019 Aug 12. doi: 10.1001/jamaneurol.2019.2368. [Epub ahead of print]

PMID:
31403680
2.

Abnormal brain development in child and adolescent carriers of mutant huntingtin.

van der Plas E, Langbehn DR, Conrad AL, Koscik TR, Tereshchenko A, Epping EA, Magnotta VA, Nopoulos PC.

Neurology. 2019 Aug 1. pii: 10.1212/WNL.0000000000008066. doi: 10.1212/WNL.0000000000008066. [Epub ahead of print]

PMID:
31371571
3.

A Pilot Follow-Up Study of Older Alcohol-Dependent COGA Adults.

Chan G, Kramer JR, Schuckit MA, Hesselbrock V, Bucholz KK, Edenberg HJ, Acion L, Langbehn D, McCutcheon V, Nurnberger JI Jr, Hesselbrock M, Porjesz B, Bierut L, Marenna BC, Cookman A, Kuperman S.

Alcohol Clin Exp Res. 2019 Aug;43(8):1759-1768. doi: 10.1111/acer.14116. Epub 2019 Jun 30.

PMID:
31141183
4.

Synthetic Photoswitchable Neurotransmitters Based on Bridged Azobenzenes.

Cabré G, Garrido-Charles A, González-Lafont À, Moormann W, Langbehn D, Egea D, Lluch JM, Herges R, Alibés R, Busqué F, Gorostiza P, Hernando J.

Org Lett. 2019 May 17;21(10):3780-3784. doi: 10.1021/acs.orglett.9b01222. Epub 2019 May 9.

PMID:
31070376
5.

Personality traits and negative consequences associated with binge drinking and marijuana use in college students.

O'Leary DS, Langbehn DR, Kramer JR, Kuperman S, Fuhrmeister LA, Vaidya JG.

Am J Drug Alcohol Abuse. 2019;45(4):400-409. doi: 10.1080/00952990.2019.1601200. Epub 2019 May 1.

PMID:
31042417
6.

Synthesis of functionalized diazocines for application as building blocks in photo- and mechanoresponsive materials.

Moormann W, Langbehn D, Herges R.

Beilstein J Org Chem. 2019 Mar 20;15:727-732. doi: 10.3762/bjoc.15.68. eCollection 2019.

7.

Association Between Age and Familial Risk for Alcoholism on Functional Connectivity in Adolescence.

Vaidya JG, Elmore AL, Wallace AL, Langbehn DR, Kramer JR, Kuperman S, O'Leary DS.

J Am Acad Child Adolesc Psychiatry. 2019 Jul;58(7):692-701. doi: 10.1016/j.jaac.2018.12.008. Epub 2019 Feb 14.

PMID:
30768382
8.

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.

Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington's Disease Network; Huntington Study Group investigators.

Lancet Neurol. 2019 Feb;18(2):165-176. doi: 10.1016/S1474-4422(18)30391-0. Epub 2018 Dec 15.

PMID:
30563778
9.

Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.

Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, Caron NS, Østergaard ME, Anderson LM, Xie Y, Cengio LD, Findlay-Black H, Doty CN, Fitsimmons B, Swayze EE, Seth PP, Raymond LA, Frank Bennett C, Hayden MR.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaar3959. doi: 10.1126/scitranslmed.aar3959.

PMID:
30282695
10.

Reliability and validity of an internalizing symptom scale based on the adolescent and adult Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA).

Acion L, Kramer J, Liu X, Chan G, Langbehn D, Bucholz K, McCutcheon V, Hesselbrock V, Schuckit M, Dick D, Hesselbrock M, Kuperman S.

Am J Drug Alcohol Abuse. 2019;45(2):151-160. doi: 10.1080/00952990.2018.1476520. Epub 2018 Jun 5.

11.

The Iowa Personality Disorder Screen: A validation study in a psychiatric population that receives long-term group psychotherapy for personality related problems.

Selvik SG, Hummelen B, Romild U, Langbehn DR, Pedersen G.

Personal Ment Health. 2018 Aug;12(3):229-240. doi: 10.1002/pmh.1418. Epub 2018 May 3.

PMID:
29722177
12.

Natural biological variation of white matter microstructure is accentuated in Huntington's disease.

Gregory S, Crawford H, Seunarine K, Leavitt B, Durr A, Roos RAC, Scahill RI, Tabrizi SJ, Rees G, Langbehn D, Orth M.

Hum Brain Mapp. 2018 Apr 22. doi: 10.1002/hbm.24191. [Epub ahead of print]

13.

Test-Retest Reliability of Measures Commonly Used to Measure Striatal Dysfunction across Multiple Testing Sessions: A Longitudinal Study.

Palmer CE, Langbehn D, Tabrizi SJ, Papoutsi M.

Front Psychol. 2018 Jan 12;8:2363. doi: 10.3389/fpsyg.2017.02363. eCollection 2017.

14.

Stimulating neural plasticity with real-time fMRI neurofeedback in Huntington's disease: A proof of concept study.

Papoutsi M, Weiskopf N, Langbehn D, Reilmann R, Rees G, Tabrizi SJ.

Hum Brain Mapp. 2018 Mar;39(3):1339-1353. doi: 10.1002/hbm.23921. Epub 2017 Dec 13.

15.

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.

Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ; TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington Study Group Investigators.

Neurology. 2017 Dec 12;89(24):2495-2502. doi: 10.1212/WNL.0000000000004743. Epub 2017 Nov 15.

16.

Cortical Thickness in Adolescents with a Family History of Alcohol Use Disorder.

Henderson KE, Vaidya JG, Kramer JR, Kuperman S, Langbehn DR, O'Leary DS.

Alcohol Clin Exp Res. 2018 Jan;42(1):89-99. doi: 10.1111/acer.13543. Epub 2017 Dec 6.

PMID:
29105114
17.

Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis.

Long JD, Mills JA, Leavitt BR, Durr A, Roos RA, Stout JC, Reilmann R, Landwehrmeyer B, Gregory S, Scahill RI, Langbehn DR, Tabrizi SJ; Track-HD and Track-On Investigators.

JAMA Neurol. 2017 Nov 1;74(11):1352-1360. doi: 10.1001/jamaneurol.2017.2107.

18.

Design optimization for clinical trials in early-stage manifest Huntington's disease.

Frost C, Mulick A, Scahill RI, Owen G, Aylward E, Leavitt BR, Durr A, Roos RAC, Borowsky B, Stout JC, Reilmann R, Langbehn DR, Tabrizi SJ, Sampaio C; TRACK-HD Investigators.

Mov Disord. 2017 Nov;32(11):1610-1619. doi: 10.1002/mds.27122. Epub 2017 Sep 14.

19.

Polyunsaturated fatty acid composition and childhood adversity: Independent correlates of depressive symptom persistence.

Coryell WH, Langbehn DR, Norris AW, Yao JR, Dindo LN, Calarge CA.

Psychiatry Res. 2017 Oct;256:305-311. doi: 10.1016/j.psychres.2017.06.036. Epub 2017 Jun 21.

20.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

PMID:
28642124
21.

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.

Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, Scahill RI, Tabrizi SJ, Zetterberg H, Langbehn D, Wild EJ.

Lancet Neurol. 2017 Aug;16(8):601-609. doi: 10.1016/S1474-4422(17)30124-2. Epub 2017 Jun 7. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

22.

Operationalizing compensation over time in neurodegenerative disease.

Gregory S, Long JD, Klöppel S, Razi A, Scheller E, Minkova L, Papoutsi M, Mills JA, Durr A, Leavitt BR, Roos RAC, Stout JC, Scahill RI, Langbehn DR, Tabrizi SJ, Rees G.

Brain. 2017 Apr 1;140(4):1158-1165. doi: 10.1093/brain/awx022. No abstract available.

23.

Huntington's disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer's disease.

Hensman Moss DJ, Flower MD, Lo KK, Miller JR, van Ommen GB, 't Hoen PA, Stone TC, Guinee A, Langbehn DR, Jones L, Plagnol V, van Roon-Mom WM, Holmans P, Tabrizi SJ.

Sci Rep. 2017 Mar 21;7:44849. doi: 10.1038/srep44849.

24.

Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease.

McColgan P, Razi A, Gregory S, Seunarine KK, Durr A, A C Roos R, Leavitt BR, Scahill RI, Clark CA, Langbehn DR, Rees G, Tabrizi SJ; Track On-HD Investigators.

Hum Brain Mapp. 2017 Jun;38(6):2819-2829. doi: 10.1002/hbm.23527. Epub 2017 Mar 15.

25.

Validation of a prognostic index for Huntington's disease.

Long JD, Langbehn DR, Tabrizi SJ, Landwehrmeyer BG, Paulsen JS, Warner J, Sampaio C.

Mov Disord. 2017 Feb;32(2):256-263. doi: 10.1002/mds.26838. Epub 2016 Nov 28.

26.

Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease.

Orth M, Gregory S, Scahill RI, Mayer IS, Minkova L, Klöppel S, Seunarine KK, Boyd L, Borowsky B, Reilmann R, Bernhard Landwehrmeyer G, Leavitt BR, Roos RA, Durr A, Rees G, Rothwell JC, Langbehn D, Tabrizi SJ; TRACK-On Investigators.

Hum Brain Mapp. 2016 Dec;37(12):4615-4628. doi: 10.1002/hbm.23332. Epub 2016 Aug 1.

PMID:
27477323
27.

Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance.

Keogh R, Frost C, Owen G, Daniel RM, Langbehn DR, Leavitt B, Durr A, Roos RA, Landwehrmeyer GB, Reilmann R, Borowsky B, Stout J, Craufurd D, Tabrizi SJ.

PLoS Curr. 2016 Jan 11;8. pii: ecurrents.hd.8060298fac1801b01ccea6acc00f97cb. doi: 10.1371/currents.hd.8060298fac1801b01ccea6acc00f97cb.

28.

The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease.

Johnson EB, Rees EM, Labuschagne I, Durr A, Leavitt BR, Roos RA, Reilmann R, Johnson H, Hobbs NZ, Langbehn DR, Stout JC, Tabrizi SJ, Scahill RI; TRACK-HD investigators.

Neuropsychologia. 2015 Dec;79(Pt A):138-46. doi: 10.1016/j.neuropsychologia.2015.10.033. Epub 2015 Oct 28.

PMID:
26519555
29.

Practice Effects and Stability of Neuropsychological and UHDRS Tests Over Short Retest Intervals in Huntington Disease.

Beglinger LJ, Adams WH, Fiedorowicz JG, Duff K, Langbehn D, Biglan K, Caviness J, Olson B, Paulsen JS.

J Huntingtons Dis. 2015;4(3):251-60. doi: 10.3233/JHD-150159.

PMID:
26444022
30.

Neuropsychiatry and White Matter Microstructure in Huntington's Disease.

Gregory S, Scahill RI, Seunarine KK, Stopford C, Zhang H, Zhang J, Orth M, Durr A, Roos RA, Langbehn DR, Long JD, Johnson H, Rees G, Tabrizi SJ, Craufurd D; Track-HD Investigators.

J Huntingtons Dis. 2015;4(3):239-49. doi: 10.3233/JHD-150160.

31.

A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease.

Bečanović K, Nørremølle A, Neal SJ, Kay C, Collins JA, Arenillas D, Lilja T, Gaudenzi G, Manoharan S, Doty CN, Beck J, Lahiri N, Portales-Casamar E, Warby SC, Connolly C, De Souza RA; REGISTRY Investigators of the European Huntington's Disease Network, Tabrizi SJ, Hermanson O, Langbehn DR, Hayden MR, Wasserman WW, Leavitt BR.

Nat Neurosci. 2015 Jun;18(6):807-16. doi: 10.1038/nn.4014. Epub 2015 May 4.

PMID:
25938884
32.

Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.

Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JR, Zetterberg H, Leavitt BR, Kuhn R, Tabrizi SJ, Macdonald D, Weiss A.

J Clin Invest. 2015 May;125(5):1979-86. doi: 10.1172/JCI80743. Epub 2015 Apr 6.

33.

Interventional differences among Huntington's disease patients by disease progression in commercial and medicaid populations.

Anderson KE, Divino V, DeKoven M, Langbehn D, Warner JH, Giuliano J, Lee WC.

J Huntingtons Dis. 2014;3(4):355-63. doi: 10.3233/JHD-140124.

PMID:
25575957
34.

Criteria for success in safety and tolerability trials.

Langbehn DR.

Lancet Neurol. 2015 Jan;14(1):24-5. doi: 10.1016/S1474-4422(14)70265-0. Epub 2014 Nov 14. No abstract available.

PMID:
25467849
35.

Scientific rigor and the art of motorcycle maintenance.

Munafò M, Noble S, Browne WJ, Brunner D, Button K, Ferreira J, Holmans P, Langbehn D, Lewis G, Lindquist M, Tilling K, Wagenmakers EJ, Blumenstein R.

Nat Biotechnol. 2014 Sep;32(9):871-3. doi: 10.1038/nbt.3004.

PMID:
25203032
36.

The potential of composite cognitive scores for tracking progression in Huntington's disease.

Jones R, Stout JC, Labuschagne I, Say M, Justo D, Coleman A, Dumas EM, Hart E, Owen G, Durr A, Leavitt BR, Roos R, O'Regan A, Langbehn D, Tabrizi SJ, Frost C.

J Huntingtons Dis. 2014;3(2):197-207. doi: 10.3233/JHD-140101.

PMID:
25062862
37.

Does interval between screening and baseline matter in HD cognitive clinical trials?

Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Caviness J, Biglan K, Olson B, Paulsen JS.

J Huntingtons Dis. 2014;3(2):139-44. doi: 10.3233/JHD-140100.

PMID:
25062857
38.

Huntington disease: natural history, biomarkers and prospects for therapeutics.

Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ.

Nat Rev Neurol. 2014 Apr;10(4):204-16. doi: 10.1038/nrneurol.2014.24. Epub 2014 Mar 11. Review.

PMID:
24614516
39.

Results of the citalopram to enhance cognition in Huntington disease trial.

Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Jorge R, Biglan K, Caviness J, Olson B, Robinson RG, Kieburtz K, Paulsen JS.

Mov Disord. 2014 Mar;29(3):401-5. doi: 10.1002/mds.25750. Epub 2013 Dec 27.

40.

The direct medical costs of Huntington's disease by stage. A retrospective commercial and Medicaid claims data analysis.

Divino V, Dekoven M, Warner JH, Giuliano J, Anderson KE, Langbehn D, Lee WC.

J Med Econ. 2013 Aug;16(8):1043-50. doi: 10.3111/13696998.2013.818545. Epub 2013 Jul 5.

PMID:
23789925
41.

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR; TRACK-HD Investigators.

Lancet Neurol. 2013 Jul;12(7):637-49. doi: 10.1016/S1474-4422(13)70088-7. Epub 2013 May 9.

PMID:
23664844
42.

Corpus callosal atrophy in premanifest and early Huntington's disease.

Crawford HE, Hobbs NZ, Keogh R, Langbehn DR, Frost C, Johnson H, Landwehrmeyer B, Reilmann R, Craufurd D, Stout JC, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Scahill RI; TRACK-HD Investigators.

J Huntingtons Dis. 2013;2(4):517-26. doi: 10.3233/JHD-130077.

PMID:
25062736
43.

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease.

Stout JC, Jones R, Labuschagne I, O'Regan AM, Say MJ, Dumas EM, Queller S, Justo D, Santos RD, Coleman A, Hart EP, Dürr A, Leavitt BR, Roos RA, Langbehn DR, Tabrizi SJ, Frost C.

J Neurol Neurosurg Psychiatry. 2012 Jul;83(7):687-94. doi: 10.1136/jnnp-2011-301940. Epub 2012 May 7.

44.

Patterns of serotonergic antidepressant usage in prodromal Huntington disease.

Rowe KC, Paulsen JS, Langbehn DR, Wang C, Mills J, Beglinger LJ, Smith MM, Epping EA, Fiedorowicz JG, Duff K, Ruggle A, Moser DJ; PREDICT-HD Investigators of the Huntington Study Group.

Psychiatry Res. 2012 Apr 30;196(2-3):309-14. doi: 10.1016/j.psychres.2011.09.005. Epub 2012 Mar 5.

45.

Predicting Disease Onset from Mutation Status Using Proband and Relative Data with Applications to Huntington's Disease.

Chen T, Wang Y, Ma Y, Marder K, Langbehn DR.

J Probab Stat. 2012 Jan 1;2012. pii: 375935.

46.

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.

Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR; TRACK-HD investigators.

Lancet Neurol. 2012 Jan;11(1):42-53. doi: 10.1016/S1474-4422(11)70263-0. Epub 2011 Dec 2.

PMID:
22137354
47.

Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy.

Scahill RI, Hobbs NZ, Say MJ, Bechtel N, Henley SM, Hyare H, Langbehn DR, Jones R, Leavitt BR, Roos RA, Durr A, Johnson H, Lehéricy S, Craufurd D, Kennard C, Hicks SL, Stout JC, Reilmann R, Tabrizi SJ; TRACK-HD investigators.

Hum Brain Mapp. 2013 Mar;34(3):519-29. doi: 10.1002/hbm.21449. Epub 2011 Nov 18.

PMID:
22102212
48.

Effects of continuity of care and patient dispositional factors on the physician-patient relationship.

Noyes R Jr, Kukoyi OA, Longley SL, Langbehn DR, Stuart SP.

Ann Clin Psychiatry. 2011 Aug;23(3):180-5.

49.

Estimating premorbid IQ in the prodromal phase of a neurodegenerative disease.

Carlozzi NE, Stout JC, Mills JA, Duff K, Beglinger LJ, Aylward EH, Whitlock KB, Solomon AC, Queller S, Langbehn DR, Johnson SA, Paulsen JS; Predict-Hd Investigators Of The Huntington Study Group.

Clin Neuropsychol. 2011 Jul;25(5):757-77. doi: 10.1080/13854046.2011.577811.

50.

Suicidal behavior in prodromal Huntington disease.

Fiedorowicz JG, Mills JA, Ruggle A, Langbehn D, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group.

Neurodegener Dis. 2011;8(6):483-90. doi: 10.1159/000327754. Epub 2011 Jun 9.

Supplemental Content

Loading ...
Support Center